Correction to: Comparison of hepatitis B vaccine efficacy in Japanese students: a retrospective study

Table 2 Positive rate of HBs antibody after HB vaccination

Vaccine Administration route	Total number	Age range, median (IQR)	HBs antibody			Positive rate (%)	Sex	Total number	Age range, median (IQR)	HBs antibody		Positive rate (%)
Vaccine Administration route	Total number	Age range, median (IQR)	Median (IQR)	(+)	(−)	Positive rate (%)	Sex	Total number	Age range, median (IQR)	(+)	(−)	Positive rate (%)
Bimmugen® subcutaneous	514	19–25, 20 (19–21)	84.9 (34.5–217) mIU/mL	473	41	92.0 ^*	Men	204	19–25, 20 (19–21)	183	21	89.7 ^†
Bimmugen® subcutaneous	514	19–25, 20 (19–21)	84.9 (34.5–217) mIU/mL	473	41	92.0 ^*	Women	310	19–22, 19 (19–19)	290	20	93.5 ^‡
Heptavax-II® subcutaneous	373	19–30, 20 (19–21)	28.7 (5–216) mIU/mL	248	125	66.3 ^*	Men	180	19–30, 20 (19–21)	102	72	56.7 ^†
Heptavax-II® subcutaneous	373	19–30, 20 (19–21)	28.7 (5–216) mIU/mL	248	125	66.3 ^*	Women	193	19–22, 19 (19–19)	146	47	75.3 ^‡
Heptavax-II® intramuscular	247	19–27, 20 (19–21)	190 (41.6–534) mIU/mL	220	27	89.1 ^*	Men	97	19–27, 20 (19–21)	79	18	81.4 ^†
Heptavax-II® intramuscular	247	19–27, 20 (19–21)	190 (41.6–534) mIU/mL	220	27	89.1 ^*	Women	150	19–22, 19 (19–20)	141	9	94.0 ^‡

^* There was a significant difference among the Bimmugen® subcutaneous, Heptavax-II® subcutaneous, and Heptavax-II® intramuscular groups (p < 0.05)
^†,‡ There were significant differences among the Bimmugen® subcutaneous, Heptavax-II® subcutaneous, and Heptavax-II® intramuscular groups in both men and women (p < 0.05)

ISSN: 1347-4715